OBJECTIVE: This scoping review aims to identify, catalogue, and characterize previously reported tools, techniques, methods, and processes that have been recommended or used by evidence synthesizers to detect fraudulent or erroneous data and mitigate its impact. INTRODUCTION: Decision-making for policy and practice should always be underpinned by the best available evidence-typically peer-reviewed scientific literature. Evidence synthesis literature should be collated and organized using the appropriate evidence synthesis methodology, best exemplified by the role systematic reviews play in evidence-based health care. However, with the rise of "predatory journals," fraudulent or erroneous data may be invading this literature, which may negatively affect evidence syntheses that use this data. This, in turn, may compromise decision-making processes. INCLUSION CRITERIA: This review will include peer-reviewed articles, commentaries, books, and editorials that describe at least 1 tool, technique, method, or process with the explicit purpose of identifying or mitigating the impact of fraudulent or erroneous data for any evidence synthesis, in any topic area. Manuals, handbooks, and guidance from major organizations, universities, and libraries will also be considered. METHODS: This review will be conducted using the JBI methodology for scoping reviews and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Databases and relevant organizational websites will be searched for eligible studies. Title and abstract, and, subsequently, full-text screening will be conducted in duplicate. Data from identified full texts will be extracted using a pre-determined checklist, while the findings will be summarized descriptively and presented in tables. REVIEW REGISTRATION: Open Science Framework https://osf.io/u8yrn.
- MeSH
- lidé MeSH
- podvod prevence a kontrola MeSH
- systematický přehled jako téma MeSH
- vědecký podvod * MeSH
- výzkumný projekt normy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Úvod a cíl: Plně digitální workflow začíná ovládat naše ordinace. Přesnost a správnost některých intraorálních skenerů je nejenom dostatečná, ale výrazně překonává klasickou technologii otiskování (sádrový model) pro účely malých protetických rekonstrukcí. U velkých rekonstrukcí je ale situace zcela jiná. Cílem tohoto přehledu bylo shrnout současné poznatky o používaných technologiích intraorálních skenerů a měření jejich přesnosti. Dalším cílem bylo zhodnocení pomůcek/přípravků a postupů zpřesňujících intraorální skenování u velkých fixních protetických rekonstrukcí. Metodika: V databázích PubMed/Medline, Scopus a Embase bylo provedeno vyhledávání na základě klíčových slov: „Intraoral scanner“, „CAD/CAM“, „Trueness“, „Precision“, „Optical impression“, „Custom-made measuring device“, „Guided implant scanning“, „Continuous scan strategy“. Výsledky byly omezeny na články publikované v anglickém jazyce v letech 2010–2024. Výsledky: Kritéria pro zařazení do našeho článku splňovalo 37 publikací. Článků popisujících technologie, se kterými pracují dostupné intraorální skenery, bylo velmi málo. Publikací, které se zaměřovaly na zpřesnění intraorálního skenovaní pomocí nových postupů nebo přípravků, bylo 21. Zbylé zahrnuté články se zabývaly srovnáváním přesnosti intraorálních skenerů mezi různými výrobky nebo srovnáním s tradičními výrobními postupy. Většina studií porovnávajících přesnost intraorálních skenerů dříve využívala měření vzdálenosti a úhlové chyby. V novějších studiích převládá metoda překrývání povrchových dat získaných 3D skenery. Pouze jedna studie využívá pyramid replacement method s Prokrustovou analýzou. Závěr: Článků zabývajících se principem intraorálních skenerů je velmi málo a ve stomatologických časopisech jde o raritu. Z analýzy dostupné literatury vyplývá, že možností zpřesnění intraorálního skenu je více. Jedná se zejména o optimalizaci trasy skenování a zapojení jiných přístrojů bez skládací chyby do protetických postupů. Nadějně vypadají zejména extraorální skenery, a hlavně zapojení protetických laboratorních skenerů. Zmenšení deformace intraorálních skenů pomocí různých přípravků pravděpodobně nepřinese požadované zpřesnění.
Introduction and aim: A fully digital workflow is increasingly dominating our surgeries. For small prosthetic reconstructions on teeth or implants, the precision and trueness of certain intraoral scanners are not only sufficient, but significantly better than the conventional technology – dental impression/plaster model. A completely different situation arises with large reconstructions. The aim of this literature review was to summarize the current knowledge on intraoral scanner technologies and their accuracy measurements. Another aim was to evaluate devices and procedures for improving the accuracy of intraoral scans in large fixed prosthetic reconstructions. Methods: The PubMed/Medline, Scopus, and Embase databases were searched using the following keywords: “Intraoral scanner”, “CAD/CAM”, “Trueness”, “Precision”, “Optical impression”, “Custom-made measuring device”, “Guided implant scanning”, “Continuous scan strategy”. The results were limited to articles published in the English language between 2010 and 2024. Results: Thirty-seven publications met the inclusion criteria. There are very few articles describing the technology used by currently available intraoral scanners. Twenty-one publications focused on improving the accuracy of intraoral scanning using new procedures or devices. The remainder of the included articles compared the accuracy of intraoral scanners across different products or compared to traditional prosthetic procedures. Most of the older studies comparing the accuracy of intraoral scanners used distance measurements and angular errors. In more recent studies, the method of superimposing surface data obtained by 3D scanners was predominant. Only one study employed the pyramid replacement method with Procrustean analysis. Conclusion: Articles addressing the principles of intraoral scanners are scarce and rarely found in dental journals. An analysis of the available literature shows that there are multiple options to improve the accuracy of intraoral scanning. These strategies primarily involve optimizing the scanning path and incorporating additional devices to avoid merging errors in the prosthetic workflow. Extraoral scanners and the use of prosthetic lab scanners are especially promising. Reducing the merging error of intraoral scans using different devices probably does not have the potential to ensure the required accuracy.
Parastomální hernie (PH) představuje významnou komplikaci u pacientů po operaci s použitím ileálního konduitu, přičemž její výskyt se podle literatury pohybuje v širokém rozmezí 10–65 %. Vzhledem k vysokému riziku a morbiditě spojené s PH se stále více zkoumá možnost prevence této komplikace pomocí profylaktické implantace síťky. Tento přístup, již úspěšně aplikovaný u jiných typů stomických operací, jako jsou kolostomie a ileostomie, slibuje podobné výhody i pro pacienty s ileálním konduitem. Tento systematický přehledový článek hodnotí šest dosavadních studií, které se zaměřují na účinnost a bezpečnost profylaktické síťky při prevenci PH. Výsledky naznačují, že implantace síťky může snížit incidenci PH při minimálním riziku komplikací, což představuje důležitý krok směrem ke zlepšení péče a kvality života pacientů podstupujících tento typ operace.
Parastomal hernia (PH) is a significant complication in patients undergoing surgery with an ileal conduit, with reported incidence rates ranging widely from 10% to 65% in the literature. Due to the high risk and morbidity associated with PH, the potential for prevention through prophylactic mesh implantation is increasingly being explored. This approach, already successfully applied in other types of stoma surgeries, such as colostomies and ileostomies, holds similar promise for patients with an ileal conduit. This systematic review article evaluates six existing studies focusing on the efficacy and safety of prophylactic mesh for PH prevention. The findings suggest that mesh implantation can reduce the incidence of PH with minimal risk of complications, representing an important step toward improved care and quality of life for patients undergoing this type of surgery.
It is now widely recognized that an inclusive approach to evidence to inform policy and practice is necessary. Although methodologies for the synthesis of qualitative and quantitative evidence are well established, the synthesis of non-research evidence remains relatively new. In 2004, JBI developed a methodological approach to synthesize this type of evidence, advocating for the unique role of textual evidence when research to inform decision-making is limited. The JBI approach has recently been revised to reflect significant changes and advances in thinking and conceptualization of conducting textual evidence systematic reviews. The evolution of this methodology and the recent changes that have been made are articulated in this paper.
- MeSH
- lidé MeSH
- medicína založená na důkazech metody MeSH
- přehledová literatura jako téma MeSH
- systematický přehled jako téma * metody MeSH
- výzkumný projekt normy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Meta-analyses, which present the best source of information on the effectiveness of interventions, are influenced by several biases. One category relates to the convenience of selective inclusion of those primary studies, which are more easily available than others. This availability bias includes bias from excluding the grey literature, bias from excluding non-English literature, and bias from excluding older studies. Existing studies are not conclusive about the impacts of this bias; in addition, none of them focus on road safety meta-analyses. To fill this gap, the present paper consisted of two studies: (1) exploring the presence of availability bias in road safety meta-analyses, and (2) demonstrating the impact of availability bias in several example meta-analyses. Based on an analysis of 80 existing meta-analyses, the first study concluded that compared to the medicine meta-analyses, the road safety meta-analyses use a longer time range, are more often restricted in terms of language, and less often involve the grey literature. The second study utilized selected unrestricted data samples to demonstrate the impact of availability bias in seven meta-analyses. The differences in intervention effectiveness in terms of crash frequency changes between unrestricted and restricted scenarios were identified. This shows that the search restrictions clearly lead to availability bias, which influences the differences in meta-analysis results.
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.0 mm or ≥ 0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies can be proposed in completely resected stage IIB-IV. In stage II only PD-1 inhibitors are approved. In stage III anti-PD-1 therapy or dabrafenib plus trametinib for patients with BRAFV600 mutated melanoma can be discussed. In resected stage IV, nivolumab can be offered, as well as ipilimumab and nivolumab, in selected, high-risk patients. In patients with clinically detected macroscopic, resectable disease, neoadjuvant therapy with ipilimumab plus nivolumab followed complete surgical resection and adjuvant therapy according to pathological response and BRAF status can be offered. Neoadjuvant therapy with pembrolizumab followed by complete surgical resection and adjuvant pembrolizumab is also recommended. For patients with disease recurrence after (neo) adjuvant therapy, further treatment should consider the type of (neo) adjuvant therapy received as well as the time of recurrence, i.e., on or off therapy. In patients with irresectable stage III/IV disease systemic treatment is always indicated. For first line treatment PD-1 antibodies alone or in combination with CTLA-4 or LAG-3 antibodies shall be considered. In stage IV melanoma with a BRAFV600 mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy, in selected cases. In patients with primary resistance to immunotherapy and harboring a BRAFV600 mutation, this therapy shall be offered as second line. Other second line therapies include therapy with tumor infiltrating lymphocytes and combinations of immune checkpoint inhibitors not used in first line. This guideline is valid until the end of 2026.
- MeSH
- konsensus * MeSH
- lidé MeSH
- melanom * terapie diagnóza patologie MeSH
- nádory kůže * terapie patologie diagnóza MeSH
- staging nádorů MeSH
- systematický přehled jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Evropa MeSH
This guideline was developed in close collaboration with multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF) and the European Organization for Research and Treatment of Cancer (EORTC). Recommendations for the diagnosis and treatment of melanoma were developed on the basis of systematic literature research and consensus conferences. Cutaneous melanoma (CM) is the most dangerous form of skin tumor and accounts for 90 % of skin cancer mortality. The diagnosis of melanoma can be made clinically and must always be confirmed by dermoscopy. If melanoma is suspected, a histopathological examination is always required. Sequential digital dermoscopy and whole-body photography can be used in high-risk patients to improve the detection of early-stage melanoma. If available, confocal reflectance microscopy can also improve the clinical diagnosis in special cases. Melanoma is classified according to the 8th version of the American Joint Committee on Cancer classification. For thin melanomas up to a tumor thickness of 0.8 mm, no further diagnostic imaging is required. From stage IB, lymph node sonography is recommended, but no further imaging examinations. From stage IIB/C, whole-body examinations with computed tomography or positron emission tomography CT in combination with magnetic resonance imaging of the brain are recommended. From stage IIB/C and higher, a mutation test is recommended, especially for the BRAF V600 mutation. It is important to perform a structured follow-up to detect relapses and secondary primary melanomas as early as possible. A stage-based follow-up regimen is proposed, which in the experience of the guideline group covers the optimal requirements, although further studies may be considered. This guideline is valid until the end of 2026.
- MeSH
- dermatoskopie metody normy MeSH
- konsensus * MeSH
- lidé MeSH
- melanom * diagnóza terapie patologie MeSH
- nádory kůže * diagnóza terapie patologie MeSH
- staging nádorů MeSH
- systematický přehled jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Proposed in the early 1980s as a solution for managing complications of portal hypertension, the percutaneous creation of transjugular intrahepatic portosystemic shunt has consistently gained a central role. Increasingly lower complication rates have been observed thanks to improvements in both technologies and the skills of interventional radiologists. PURPOSE: This document is aimed at interventional radiologists and provides best practice recommendations for transjugular intrahepatic portosystemic shunt creation, describing patient selection, intraprocedural management and follow-up, in addition to recommendations in paediatric settings. METHODS: The CIRSE Standards of Practice Committee established a writing group consisting of seven European clinicians with recognised expertise in the creation of transjugular intrahepatic portosystemic shunt. The writing group reviewed the existing literature performing a pragmatic evidence search using PubMed to select relevant publications in the English language and involving human subjects, preferably published from 2009 to 2024. The final recommendations were developed by consensus. RESULTS: TIPS creation has an established role in the successful management of portal hypertension and its complications. This Standards of Practice document provides up-to-date recommendations for patient selection, materials, its safe performance, and follow-up with complications management.
- MeSH
- dítě MeSH
- intervenční radiologie * normy MeSH
- lidé MeSH
- portální hypertenze * chirurgie MeSH
- přehledová literatura jako téma MeSH
- transjugulární intrahepatální portosystémový zkrat * normy MeSH
- výběr pacientů MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
[Scleral Grafts in Ophthalmic Surgery. A Review]
Cíle: Shrnout historii i současné trendy ve využití sklérálních štěpů v oftalmologii. Materiál a metody: Provedli jsme analýzu literatury prostřednictvím databází MEDLINE a Cochrane Library. Hledaná hesla byla “sclera”, “graft”, “surgery”. Výsledkem vyhledávání bylo 1596 článků, z nichž jsme 192 vyhodnotili jako relevantní. Relevantní články byly seřazeny chronologicky a dle způsobu využití sklerálních štěpu, což umožnilo vypracování přehledového článku. Výsledky: Skléra se v oftalmologii rutinně používá od padesátých let dvacátého století, a to v mnoha různých indikacích. Některé z nich se časem staly prakticky obsoletními (například využití při operačním řešení amoce sítnice), ale velká část nachází uplatnění dodnes (zejména využití v glaukomové či okuloplastické chirurgii, případně jako záplata při defektu skléry nebo rohovky). Závěr: I přesto, že je v současné době alogenní skléra oproti jiným produktům tkáňového bankovnictví v oftalmologii využívána spíše méně často a okruh jejích indikací se částečně zúžil, zůstává vzhledem ke své dostupnosti a vlastnostem užitečným a perspektivním materiálem.
Aim: To summarize the history and current trends in the use of scleral grafts in ophthalmology. Materials and methods: We conducted a review of the literature through the MEDLINE and Cochrane Library databases. The search terms were "sclera", "graft", and "surgery". The search resulted in 1596 articles, of which we evaluated 192 as relevant. The relevant articles were sorted chronologically and according to the method of using scleral grafts, which enabled the development of a review article. Results: The sclera has been routinely used in ophthalmology since the 1950s in many different indications. Some of these indications have become practically obsolete over time (for example, use in the surgical management of retinal detachment), but a large number still find application today (especially use in glaucoma or oculoplastic surgery, or as a patch for a defect in the sclera or cornea). Conclusion: Even though allogeneic sclera is currently used less frequently in ophthalmology compared to other tissue banking products and the range of its indications has partially narrowed, it remains a useful material due to its availability and properties.
- MeSH
- alografty * klasifikace MeSH
- dějiny 20. století MeSH
- lidé MeSH
- oftalmologické chirurgické výkony dějiny klasifikace metody MeSH
- přehledová literatura jako téma MeSH
- skléra * chirurgie MeSH
- skleroplastika dějiny klasifikace metody MeSH
- transplantáty dějiny klasifikace MeSH
- vitreoretinální chirurgie dějiny klasifikace metody MeSH
- Check Tag
- dějiny 20. století MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Fortunately, as much as two thirds of this disease's burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that, with respect to low-density lipoprotein cholesterol (LDL-C), "lower is better for longer", and recent data have strongly emphasised the need for also "the earlier the better". In addition to statins, which have been available for several decades, ezetimibe, bempedoic acid (also as fixed dose combinations), and modulators of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors and inclisiran) are additionally very effective approaches to LLT, especially for those at very high and extremely high cardiovascular risk. In real life, however, clinical practice goals are still not met in a substantial proportion of patients (even in 70%). However, with the options we have available, we should render lipid disorders a rare disease. In April 2021, the International Lipid Expert Panel (ILEP) published its first position paper on the optimal use of LLT in post-ACS patients, which complemented the existing guidelines on the management of lipids in patients following ACS, which defined a group of "extremely high-risk" individuals and outlined scenarios where upfront combination therapy should be considered to improve access and adherence to LLT and, consequently, the therapy's effectiveness. These updated recommendations build on the previous work, considering developments in the evidential underpinning of combination LLT, ongoing education on the role of lipid disorder therapy, and changes in the availability of lipid-lowering drugs. Our aim is to provide a guide to address this unmet clinical need, to provide clear practical advice, whilst acknowledging the need for patient-centred care, and accounting for often large differences in the availability of LLTs between countries.
- MeSH
- akutní koronární syndrom * krev farmakoterapie etiologie MeSH
- anticholesteremika terapeutické užití MeSH
- ateroskleróza * krev komplikace farmakoterapie MeSH
- hypolipidemika * terapeutické užití MeSH
- LDL-cholesterol krev MeSH
- lidé MeSH
- přehledová literatura jako téma MeSH
- statiny terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH